T Cell Receptor
Astellas partners with Adaptimmune to develop off-the-shelf CAR-T and T-cell therapies
Astellas Pharma announced a research and commercialization deal with Adaptimmune for the codevelopment of new stem cell-derived allogeneic chimeric antigen receptor and other T-cell therapies for the treatment of cancer.
Cytovia partners with UCSF, New York Stem Cell Foundation to develop novel CAR-NK cell therapies
Cytovia Therapeutics announced research partnerships with both The New York Stem Cell Foundation Research Institute and University of California, San Francisco, for the development of induced pluripotent stem cell-derived chimeric antigen receptor-natural killer cell therapies for cancer.
MD Anderson, Ziopharm renew R&D agreement to include T-cell receptor-based therapies
The University of Texas MD Anderson Cancer Center has announced a new research and development agreement with partner Ziopharm Oncology for the development of neoantigen-specific T-cell receptors, a cell-based therapy used to treat various forms of cancer.
TCR-engineered T Cells in Solid Tumors (ACTengine)
HA-1 T TCR T Cell Immunotherapy for the Treating of Patients with Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Developing a Pause Button for CAR T-Cell Therapy
Chimeric antigen receptor T-cell therapy has proven to be a life-changing development for those with advanced, treatment refractory leukemia and lymphoma for whom other therapies have proven ineffective. But if we apply Newton’s law of motion to medicine, when CAR T-cell therapy effectively targets and kills cancer cells, an opposite reaction from the immune system causes treatment related-toxicities that can endanger the life of patients.
T-cell therapy receives FDA’s orphan drug status for soft tissue sarcoma
The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell therapy, for the treatment of soft tissue sarcomas.